Exact FDA event identifier

Event 82424

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: March 19, 2019
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: Allergan Sales, LLC

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% 5 mL bottles, Rx only, Allergan, Inc. Irvine, CA 92612 U.S.A. NDC 0023-9211-05

D-1056-2019

Recall number: D-1056-2019
Initiated: March 19, 2019
Classification: Class II
Status: Terminated
Recalling firm: Allergan Sales, LLC
Quantity: 72 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

cGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot#: 99946 Exp. January 16, 2021

Distribution pattern

TN only